RYTM - Rhythm Pharmaceuticals EPS in-line misses on revenue August, 03 2021 07:16 AM Rhythm Pharmaceuticals Inc. Rhythm Pharmaceuticals (NASDAQ:RYTM): Q2 GAAP EPS of -$0.70 in-line. Revenue of $0.27M misses by $0.28M. Press Release For further details see: Rhythm Pharmaceuticals EPS in-line, misses on revenue